|
CN111056967A
|
|
Synthetic method of 3-methyl-4-amino-N- (4-amino-2-methyl-phenyl) -benzamide
|
|
CN110664769A
|
|
Lanthanum carbonate orally disintegrating tablet and preparation method thereof
|
|
CN110818551A
|
|
Synthetic method of 3,3',4,4' -biphenyltetracarboxylic acid
|
|
CN110693843A
|
|
Lurasidone hydrochloride hydrophilic gel skeleton tablet and preparation method thereof
|
|
CN110590596A
|
|
Preparation method of 4,4' -diamino-2, 2' -dimethyl-1, 1' -biphenyl
|
|
CN110577500A
|
|
Preparation method of 2- (aminophenyl) -5-aminobenzoxazole
|
|
CN110627669A
|
|
Preparation method of 1, 3-propylene glycol bis (4-aminobenzoic acid) ester
|
|
CN110437078A
|
|
The preparation method of bis- [4- aminophenyl] fluorene derivatives of 9,9-
|
|
CN110437083A
|
|
The synthetic method of aramine enantiomter
|
|
CN110274966A
|
|
Method in relation to substance in high effective liquid chromatography for measuring tolvaptan bulk pharmaceutical chemicals
|
|
CN109776447A
|
|
Acotiamide hydrochloride hydrate industrialized preparing process
|
|
CN109646391A
|
|
Tolvaptan sustained release preparation and preparation method thereof
|
|
CN109528636A
|
|
Tolvaptan oral administration solution and preparation method thereof
|
|
CN109456213A
|
|
The preparation method of p-aminobenzoic acid
|
|
CN109608368A
|
|
The synthesis of N- [4- (1- amino-ethyl) -2,6- difluorophenyl] Methanesulfomide and method for splitting
|
|
CN109078007A
|
|
The preparation method of sodium rabeprazole enteric-coated sustained-release micro-spheres and oral solid formulation containing sodium rabeprazole enteric-coated sustained-release micro-spheres
|
|
CN108836973A
|
|
Metformin-glibenclamide capsule and preparation method thereof
|
|
CN109134373A
|
|
The preparation method of tolvaptan nanocrystal and oral solid formulation containing tolvaptan nanocrystal
|
|
CN108947854A
|
|
The method for splitting of aramine and its isomers
|
|
CN108341780A
|
|
The preparation method of tolvaptan intermediate
|
